Phares Drug Delivery AG

Phares has developed technologies that can improve the chances for successful formulation development of poorly soluble compounds. Phares' highly qualified team has extensive international experience and successful track record in pharmaceutical R&D, extending from early feasibility to full development of dosage forms for oral, parenteral and topical administration routes.

Activity:

- Licensing & Business Development
- Research & Development
- Other Industry Services

Product / Technology type(s) covered:

- Drug delivery
- Technology

Therapeutic targets:

- AIDS
- Allergy
- Arthritis / Rheumato
- Cancer
- Cardiovascular
- Central nervous system
- Dermatology
- Diabetes
- Gastrointestinal
- Hematology
- Infectious Diseases
- Obesity
- Oncology
- Pain
- Pediatrics
- Reproductive Health
- Stroke
- Transplant
- Women's Health

Markets Covered

a. HeadQuarter: Netherlands

b. Continent(s) active: North America , Europe , Far East

c. Countries active: US, Germany, Unitied Kingdom, Belgium, Japan, France, Italy, Danemark, Sweden,

Corporate data:

Number of Employees: 24

Turnover:

Amount:	Year:	Currency:
Private company	2001	Euro

Year founded: 2000

Partners / Alliances: Phares has two partnering models. Firstly, we provide enabling screening and delivery technologies to a broad base of companies to screen and formulate novel insoluble compounds. Our partners are fully integrated Pharma companies and small to medium sized biopharmaceutical companies. Secondly, we co-develop innovative products for out-licensing.